Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 306 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
LETTER TO THE EDITOR
Year : 2020  |  Volume : 24  |  Issue : 4  |  Page : 373-374

An unusual case of fragile X associated primary ovarian insufficiency


1 Department of Endocrinology, Silverline Hospital, Kochi, Kerala, India
2 Scientific Applications and Support, Neuberg Anand Reference Laboratory, Bangalore, Karnataka, India

Date of Submission12-May-2020
Date of Decision29-May-2020
Date of Acceptance06-Jun-2020
Date of Web Publication27-Aug-2020

Correspondence Address:
Karthik Subramaniam
Consultant Endocrinologist, KP Vallom Road, Kadavanthara PO, Kochi - 682 020, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijem.IJEM_290_20

Rights and Permissions

How to cite this article:
Subramaniam K, Prasad HK. An unusual case of fragile X associated primary ovarian insufficiency. Indian J Endocr Metab 2020;24:373-4

How to cite this URL:
Subramaniam K, Prasad HK. An unusual case of fragile X associated primary ovarian insufficiency. Indian J Endocr Metab [serial online] 2020 [cited 2020 Sep 24];24:373-4. Available from: http://www.ijem.in/text.asp?2020/24/4/373/293603



Sir,

Premature ovarian insufficiency (POI) is defined as ovarian failure in women of age <40 years. Here is a report of an adolescent girl with few unusual features in a genetic POI.

A 20-year-old girl, presented with the complaints of attenuated breast development and scanty menstrual periods. At 18 years of age, after unsuccessful naturopathic treatment, she consulted a gynecologist for primary amenorrhea. Her FSH was 68 U/L and LH 46 U/L. Her karyotype was 46 XX in 30 metaphases and subsequently, she was started on combined oral contraceptive pills. She consulted us after 2 years as there was only mild improvement in symptoms.

Her maternal cousin had intellectual impairment by birth and expired at the age of 12 due to severe lung infection. Her brother was hyperactive since childhood. She weighed 52 kg and her height was 154 cm. She had normal mentation, elongated face with low set ears; breast - tanner 3, pubic hair - tanner 2, and labia majora was not fully developed. She had no features of autoimmunity or hepatosplenomegaly. She had no neurocognitive problems, behavioral or psychiatric disorders.

Karyotype was repeated with 50 metaphases, which again was normal. Triple repeat-”primed polymerase chain reaction (TP-PCR) for detecting premutations in Fragile X Mental Retardation 1 (FMR-1) gene showed 134/151 CGG repeats [Figure 1]a and hence was diagnosed as Fragile X associated POI (FXPOI). She and her parents were counseled regarding limited fertility potential. She was started on daily estradiol valerate 1 mg in view of suboptimal breast development. Her parents and brother had normal repeats [Figure 1]b.
Figure 1: (a) Electropherogram of the proband showing detection of peak at 134/151 CGG repeats. (b) Normal electropherogram of the father (27 repeats), brother (35 repeats), and mother (29/35 repeats) of the proband

Click here to view


Fragile X syndrome (FXS) is caused when there is expansion of CGG trinucleotides (>200) in untranslated region of FMR-1 and subsequent hypermethylation of CGG trinucleotides or CpG island.[1] Repeats between 55 and 200 are called premutations and results in FXPOI and fragile X associated tremor/ataxia syndrome (FXTAS).[2]

One-third of premutation carriers (PC) are thought to have FXPOI (includes varied phenotype like reduced AMH; increased FSH; oligomenorrhoea and early menopause). About 3% of girls with PC have oligomenorrhoea and <1% have cessation of menses during adolescence.[3] We were unable to find any reports of primary amenorrhea, though secondary amenorrhea with as few as 3 cycles been reported in adolescents.[4] The prevalence of PC was 2% in POI, 0.7% in early menopause, and 0.4% in controls.[5] The pathophysiology of FXPOI are (a) increased levels of expanded FMR1 mRNA causing gain-of-function toxicity; (b) repeat associated non-ATG translation causing intranuclear inclusions; (c) association with long non-coding RNA and antisense transcripts, and (d) increased transcriptional activity resulting in DNA damage.[2]

Expansion of premutation to full mutation usually occurs through woman and very rarely through men.[1] Here, both parents had normal repeats yet the girl had biallelic premutation. Whether such biallelic PC has a more profound effect on phenotype is not known. One important factor determining the instability of repeats, causing expansion, is AGG interruptions.

The unique features in this case were PC presentation as primary amenorrhea. Mid-range CGG repeats (80–99) is usually associated with FXPOI but in our case it was very much higher (134/151 repeats) than reported in literature.[3] Paternal expansion of repeats into PC was another distinguishing feature.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: Diagnostic and carrier testing. Genet Med 2005;7:584-7.  Back to cited text no. 1
    
2.
Mila M, Alvarez-Mora MI, Madrigal I, Rodriguez-Revenga L. Fragile X syndrome: An overview and update of the FMR1 gene. Clin Genet 2018;93:197-205.  Back to cited text no. 2
    
3.
Wheeler A, Raspa M, Hagerman R, Mailick M, Riley C. Implications of the FMR1 premutation for children, adolescents, adults, and their families. Pediatrics 2017;139(Suppl 3):S172-S82.  Back to cited text no. 3
    
4.
Conway GS, Payne NN, Webb J, Murray A, Jacobs PA. Fragile X premutation screening in women with premature ovarian failure. Hum Reprod 1998;13:1184-7.  Back to cited text no. 4
    
5.
Murray A, Schoemaker MJ, Bennett CE, Ennis S, Macpherson JN, Jones M, et al. Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency. Genet Med 2014;16:19-24.  Back to cited text no. 5
    


    Figures

  [Figure 1]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

   Article Figures
  In this article
 References

 Article Access Statistics
    Viewed125    
    Printed0    
    Emailed0    
    PDF Downloaded32    
    Comments [Add]    

Recommend this journal